Bristol-Myers Squibb

BMY

Market cap $88.8B

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Shares of Bristol Myers BMY continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry's gain of 4.8%.

Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.

Bristol Myers Squibb remains undervalued, ranking 12th on my Magic Formula screen with strong earnings yield and capital returns amongst the S&P 500. Company pivoting from small-molecule drugs to mRNA and gene therapies via BioNTech partnership and Orbital Therapeutics acquisition. Growth portfolio offsetting legacy drug declines, but key patents like Eliquis and Opdivo face expirations by 2028.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types.

REDMOND, Wash. , Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs.

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deliver 23.93% to 38.57% net gains by October 2026, based on analyst targets. Stocks like CAG, VZ, DOC, BMY, KVUE, CPB, UDR, VTRS, KIM, TFC, KEY, HPQ, T, and RF meet the ideal of dividends from $1K invested exceeding share price.

Bristol Myers Squibb offers a compelling value entry for long-term income investors, despite looming patent cliffs and execution risks. BMY's growth portfolio is positioned to offset revenue losses from Eliquis and Opdivo expirations, supporting a moderate long-term revenue CAGR. Current valuations reflect excessive pessimism, trading at a 25% discount to BMY's five-year average, with downside risk already priced in.

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.